Ibuprofen Monograph, NDA Drug Quality Should Be Equivalent, Law Firm Says
This article was originally published in The Tan Sheet
Executive Summary
FDA must require the same level of quality for ibuprofen products approved under both OTC monographs and NDAs if it decides to add the ingredient to the internal analgesics tentative final monograph, a Washington, D.C. law firm says in Oct. 3 comments.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning